Carl Zeiss Meditec Nine‑Month Results
Carl Zeiss Meditec disclosed that nine‑month revenue amounted to €1.55 billion, representing a 2.9% decline from the comparable period, although the figure is flat when adjusted for currency effects. The adjusted EBITA margin contracted to 8.0%, down from 11.1% in the prior‑year period, a deterioration attributed to negative currency effects and weaker consumables sales.
The ophthalmology segment experienced a revenue drop, primarily driven by softer demand in China and the withdrawal of an intraocular lens product. The company removed a bifocal lens from a procurement tender, which triggered inventory returns and further weakened the intraocular lens business in China.
In the refractive laser business, sales fell owing to lower procedure volumes and a softer investment environment for equipment, especially across the Asia‑Pacific region. Conversely, the microsurgery unit recorded growth, supported by strong deliveries of neurosurgical operating microscopes.
Looking ahead, Carl Zeiss Meditec projects full‑year fiscal 2025/26 revenue of approximately €2.15 billion to €2.20 billion and an adjusted EBITA margin in the range of 8% to 10%. The company also anticipates a goodwill impairment of roughly €150 million in its Ophthalmology strategic business unit in the fourth quarter of fiscal 2025/26.